However, the current study is the first to use this tool to assess in vivo activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in a BC population while receiving chemotherapy. This evidence concerns the gene CYP2C19 and breast cancer.